Radiation enhances adenoviral genetherapy in pancreatic cancer via activation of cytomegalovirus promoter and increased adenovirus uptake

Clinical Cancer Research

Volumn 14, Issue 6, 2008, Pages 1859-1867

  Egami, Takuya ^a   Ohuchida, Kenoki ^a   Mizumoto, Kazuhiro ^a   Onimaru, Manabu ^a   Toma, Hiroki ^a   Nishio, Shoko ^a   Nagai, Eishi ^a   Matsumoto, Kunio ^b   Nakamura, Toshikazu ^b   Tanaka, Masao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; DYNAMIN II; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NK 4; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER RADIOTHERAPY; CANCER THERAPY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOMEGALOVIRUS; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; EMBRYO; FEMALE; GENE ACTIVATION; GENE THERAPY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION;

ADENOVIRIDAE; ANIMALS; CELL LINE, TUMOR; CYTOMEGALOVIRUS; DYNAMIN II; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PANCREATIC NEOPLASMS; PLASMIDS; PROMOTER REGIONS (GENETICS); TRANSDUCTION, GENETIC; VIRUS INTERNALIZATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 41549114263     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0933     Document Type: Article

References (49)

1. Sohn TA, Yeo CJ. The molecular genetics of pancreatic ductal carcinoma: a review. Surg Oncol 2000;9:95-101.
2. Kountouras J, Zavos C, Chatzopoulos D. New concepts of molecular biology on gastric carcinogenesis. Hepatogastroenterology 2005;52:1305-12.
3. Takayama T, Miyanishi K, Hayashi T, Sato Y, Niitsu Y. Colorectal cancer: genetics of development and metastasis. J Gastroenterol 2006;41:185-92.
4. Benito M, Diaz-Rubio E. Molecular biology in colorectal cancer. Clin Transl Oncol 2006;8:391-8.
5. Weiner LM, Borghaei H. Targeted therapies in solid tumors: monoclonal antibodies and small molecules. Hum Antibodies 2006;15:103-11.
6. MacKenzie MJ. Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 2004;5:541-9.
7. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol 2006;133:9-29.
8. Gunzburg WH, Salmons B. Novel clinical strategies for the treatment of pancreatic carcinoma. Trends Mol Med 2001;7:30-7.
9. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
10. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP. Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 1995;82:111-5.
11. Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nature Rev 2002;2:897-909.
12. Jaffee EM, Hruban RH, Canto M, Kern SE. Focus on pancreas cancer. Cancer cell 2002;2:25-8.
13. Di Renzo MF, Poulsom R, Olivero M, Comoglio PM, Lemoine NR. Expression of the Met/hepatocyte growth factor receptor in human pancreatic cancer. Cancer Res 1995;55:1129-38.
14. Bloomston M, Zervos EE, Rosemurgy AS II. Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 2002;9:668-74.
15. Jimeno A, Hidalgo M. Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol Cancer Ther 2006;5:787-96.
16. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg 2006;13:286-95.
17. Ogura Y, Mizumoto K, Nagai E, et al. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther 2006;13:520-9.
18. Murakami M, Nagai E, Mizumoto K, et al. Suppression of metastasis of human pancreatic cancer to the liver by transportal injection of recombinant adenoviral NK4 in nude mice. Int J Cancer 2005;117:160-5.
19. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther 2001;8:308-15.
20. Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004;22:1389-97.
21. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 2003;66:1-9.
22. Geoerger B, Grill J, Opolon P, et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. Br J Cancer 2003;89:577-84.
23. Portella G, Pacelli R, Libertini S, et al. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 2003;88:5027-32.
24. Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000;60:1193-6.
25. Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M, Nakamura T. NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br J Cancer 2001;84:864-73.
26. Maehara N, Nagai E, Mizumoto K, et al. Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin Exp Metastasis 2002;19:417-26.
27. Saimura M, Nagai E, Mizumoto K, et al. Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nudemice. Cancer Gene Ther 2002;9:799-806.
28. Qian LW, Mizumoto K, Urashima T, et al. Radiation-induced increase in invasive potential of human pancreatic cancer cells and its blockade by a matrix metalloproteinase inhibitor, CGS27023. Clin Cancer Res 2002;8:1223-7.
29. Ohuchida K, Mizumoto K, Murakami M, et al. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 2004;64:3215-22.
30. Nakamura T, Nishizawa T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
31. Seki T, Ihara I, Sugimura A, et al. Isolation and expression of cDNA for different forms of hepatocyte growth factor from human leukocyte. Biochem Biophys Res Commun 1990;172:321-7.
32. Maemondo M, Narumi K, Saijo Y, et al. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF antagonist NK4 for cancer therapy. Mol Ther 2002;5:177-85.
33. McGrory WJ, Bautista DS, Graham FL. A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 1988;163:614-7.
34. Korst RJ, Bewig B, Crystal RG. In vitro and in vivo transfer and expression of human surfactant SP-A- and SP-B-associated protein cDNAs mediated by replication-deficient, recombinant adenoviral vectors. Hum Gene Ther 1995;6:277-87.
35. Date K, Matsumoto K, Shimura H, Tanaka M, Nakamura T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett 1997;420:1-6.
36. Sato N, Maehara N, Mizumoto K, et al. Telomerase activity of cultured human pancreatic carcinoma cell lines correlates with their potential for migration and invasion. Cancer 2001;91:496-504.
37. Zhang M, Li S, Li J, Ensminger WD, Lawrence TS. Ionizing radiation increases adenovirus uptake and improves transgene expression in intrahepatic colon cancer xenografts. Mol Ther 2003;8:21-8.
38. Qian J, Yang J, Dragovic AF, Abu-Isa E, Lawrence TS, Zhang M. Ionizing radiation-induced adenovirus infection is mediated by Dynamin 2. Cancer Res 2005;65:5493-7.
39. Ohuchida K, Mizumoto K, Ohhashi S, et al. S100A11, a putative tumor suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res 2006;12:5417-22.
40. Bruening W, Giasson B, Mushynski W, Durham HD. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res 1998;26:486-9.
41. Chen J, Stinski MF. Role of regulatory elements and the MAPK/ERK or p38 MAPK pathways for activation of human cytomegalovirus gene expression. J Virol 2002;76:4873-85.
42. Raju U, Gumin GJ, Noel F, Tofilon PJ. IκBα degradation is not a requirement for the X-ray-induced activation of nuclear factor κB in normal rat astrocytes and human brain tumor cells. Int J Radiat Biol 1998;74:617-24.
43. Benedict CA, Angulo A, Patterson G, et al. Neutrality of the canonical NF-κB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro. J Virol 2004;78:741-50.
44. Patterson S, Russell WC. Ultrastructural and immunofluorescence studies of early events in adenovirus-HeLa cell interactions. J Gen Virol 1983;64:1091-9.
45. Varga MJ, Weibull C, Everitt E. Infectious entry pathway of adenovirus type 2. J Virol 1991;65:6061-70.
46. Takei K, McPherson PS, Schmid SL, De Camilli P. Tubular membrane invaginations coated by dynamin rings are induced by GTP-γS in nerve terminals. Nature 1995;374:186-90.
47. Qian LW, Mizumoto K, Inadome N, et al. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer 2003;104:542-9.
48. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004;6 Suppl 1:S152-63.
49. Marsh M, Helenius A. Virus entry: open sesame. Cell 2006;124:729-40.